Autologous Stem Cell Transplantation with PCR-Negative Graft Would Be Associated with a Favorable Outcome in Core-Binding Factor Acute Myeloid Leukemia

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 11, 2008, Pages 1262-1269

  Nakasone, Hideki ^a   Izutsu, Koji ^a   Wakita, Satoshi ^b   Yamaguchi, Hiroki ^b   Muramatsu Kida, Michiko ^a   Usuki, Kensuke ^a  

^a Kanto Teishin Hospital   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Autologous stem cell transplantation; Core binding factor acute myeloid leukemia; Minimal residual disease; Polymerase chain reaction

Indexed keywords

BUSULFAN; CORE BINDING FACTOR; CYTARABINE; DAUNORUBICIN; ENOCITABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MERCAPTOPURINE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CANCER SURVIVAL; CD34 SELECTION; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HERPES ZOSTER; HUMAN; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL; POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT INDICATION;

ADULT; AGED; CORE BINDING FACTORS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM, RESIDUAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POLYMERASE CHAIN REACTION; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 53749095234     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.08.012     Document Type: Article

References (36)

1. Byrd J.C., Mrózek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100 (2002) 4325-4336
2. Nucifora G., and Rowley J.D. The AML1 and ETO genes in acute myeloid leukemia with a t(8;21). Leuk Lymphoma 14 (1994) 353-362
3. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92 (1998) 2322-2333
4. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96 (2000) 4075-4083
5. Narimatsu H., Yokozawa T., Iida H., et al. Clinical characteristics and outcomes in patients with t(8;21) acute myeloid leukemia in Japan. Leukemia 22 (2008) 428-432
6. Bloomfield C.D., Lawrence D., Byrd J.C., et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58 (1998) 4173-4179
7. Byrd J.C., Dodge R.K., Carroll A., et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17 (1999) 3767-3775
8. Schlenk R.F., Benner A., Krauter J., et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 22 (2004) 3741-3750
9. Marcucci G., Mrózek K., Ruppert A.S., et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 23 (2005) 5705-5717
10. Nguyen S., Leblanc T., Fenaux P., et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood 99 (2002) 3517-3523
11. Baer M.R., Stewart C.C., Lawrence D., et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 90 (1997) 1643-1648
12. Byrd J.C., Weiss R.B., Arthur D.C., et al. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol 15 (1997) 466-475
13. Martín G., Barragán E., Bolufer P., et al. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement. Haematologica 85 (2000) 699-703
14. Schlenk R.F., Benner A., Hartmann F., et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia 17 (2003) 1521-1528
15. Delaunay J., Vey N., Leblanc T., et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood 102 (2003) 462-469
16. Paschka P., Marcucci G., Ruppert A.S., et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24 (2006) 3904-3911
17. Erickson P., Gao J., Chang K.S., et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 80 (1992) 1825-1831
18. Urbano-Ispizua A., Schmitz N., de Witte T., et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 29 (2002) 639-646
19. Indication guideline of hematopoietic stem cell transplantation. The Japan Society of Hematopoietic Cell Transplantation. http://www.jshct.com/guideline/pdf/2002.pdf
20. Gondo H., Harada M., Miyamoto T., et al. Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia. Bone Marrow Transplant 20 (1997) 821-826
21. Krauter J., Wattjes M.P., Nagel S., et al. Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. Br J Haematol 107 (1999) 80-85
22. Claxton D.F., Liu P., Hsu H.B., et al. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood 83 (1994) 1750-1756
23. Poirel H., Radford-Weiss I., Rack K., et al. Detection of the chromosome 16 CBF beta-MYH11 fusion transcript in myelomonocytic leukemias. Blood 85 (1995) 1313-1322
24. Erard V., Guthrie K.A., Varley C., et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 110 (2007) 3071-3077
25. Visani G., Lemoli R., Tosi P., et al. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells. Bone Marrow Transplant 24 (1999) 467-472
26. Thomas X., Suciu S., Rio B., et al. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. Haematologica 92 (2007) 389-396
27. Miyamoto T., Nagafuji K., Harada M., et al. Quantitative analysis of AML1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukaemia. Br J Haematol 91 (1995) 132-138
28. Irving J.A., Lennard A., Storey N., et al. Analysis of CD34 populations in mobilised peripheral blood stem cell harvests and in bone marrow by fluorescent in situ hybridisation for the bcr/abl gene fusion in patients with chronic granulocytic leukaemia. Leukemia 13 (1999) 944-949
29. Clutterbuck R.D., Newman A., Powles R., Catovsky D., and Millar J.L. G-CSF mobilization of haemopoietic cell populations in SCID mice engrafted with human leukaemia. Bone Marrow Transplant 20 (1997) 325-332
30. Brenner M.K., Rill D.R., Moen R.C., et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341 (1993) 85-86
31. Testoni N., Lemoli R.M., Martinelli G., et al. Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients: evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods. Bone Marrow Transplant 22 (1998) 1065-1070
32. Jurlander J., Caligiuri M.A., Ruutu T., et al. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic transplantation for t(8;21) leukemia. Blood 88 (1996) 2183-2191
33. Miyamoto T., Nagafuji K., Akashi K., et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 87 (1996) 4789-4796
34. Guerrasio A., Pilatrino C., De Micheli D., et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 16 (2002) 1176-1181
35. Mitterbauer M., Mitterbauer-Hohendanner G., Sperr W.R., et al. Molecular disease eradication is a prerequisite for long-term remission in patients with t(8;21) positive acute myeloid leukemia: a single center study. Leuk Lymphoma 45 (2004) 971-977
36. Perea G., Lasa A., Aventín A., et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia 20 (2006) 87-94